Eli Lilly reported a 48% year-on-year revenue increase to $22.97 billion, driven by strong sales of GLP-1 drugs Mounjaro and Zepbound, which make up about 65% of total revenue. The company raised its 2026 revenue guidance to $85 billion–$87 billion, reflecting confidence in continued growth supported by strategic acquisitions, manufacturing expansion, and a diverse late-stage drug pipeline. Analysts see few obstacles to further stock gains, with potential market cap growth beyond $1.5 trillion as Eli Lilly aims for $150 billion in annual revenues by 2035.
Eli Lilly will present mid-stage trial results for eloraTZP, a two-drug obesity treatment, on September 30. The data will show if the combo offers significantly better weight loss and tolerability than tirzepatide alone, crucial for sustaining the co...
The FDA has granted full approval to Eli Lilly's Inluriyo (imlunestrant) combined with Verzenio (abemaciclib) for treating adults with estrogen receptor-positive (ER+), HER2-negative, ESR1-mutated advanced or metastatic breast cancer after progressio...
